Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513728 | 0.78 | NAALAD2 (0.43) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL7914664 | 0.76 | NAALAD2 (0.42) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL10577535 | 0.76 | NAALAD2 (0.42) | NAALAD2FOLH1CYP1A2ALDH1A1MEN1 | |
| SCHEMBL19805240 | 0.74 | GABRP (0.48) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL21052347 | 0.74 | CYP1A2 (0.48) | NAALAD2FOLH1CYP1A2ALDH1A1MEN1 | |
| SCHEMBL12655754 | 0.73 | ALDH1A1 (0.46) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL10941022 | 0.73 | TSHR (0.41) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL7918002 | 0.73 | TSHR (0.42) | NAALAD2CYP1A2ALDH1A1MEN1THRB | |
| SCHEMBL27715972 | 0.73 | NAALAD2 (0.39) | NAALAD2FOLH1CYP1A2ALDH1A1MEN1 | |
| SCHEMBL10577675 | 0.72 | NAALAD2 (0.46) | NAALAD2FOLH1CYP1A2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | claimed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | claimed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | claimed |
| CN-116514903-A | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-107074879-B | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3031810-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1838715-A2 | METHOD FOR THE PREPARATION OF MAYTANSINOID ESTERS | Immunogen, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| WO-2006078809-A2 | METHOD FOR THE PREPARATION OF MAYTANSINOID ESTERS | IMMUNOGEN, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | IMMUNOGEN, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1651162-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | Immunogen, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | SPR, SDAD1, ARRB1 | NAALAD2 1893/4885FOLH1 147/4885CYP1A2 3053/4885 |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | NAALAD2 617/4885FOLH1 523/4885CYP1A2 3419/4885 |
| US-20060167245-A1 | Method for the preparation of maytansinoid esters | PTMS, CYP4A11, CYP11B1 | NAALAD2 1081/4885FOLH1 648/4885CYP1A2 280/4885 |
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | NAALAD2 1996/4885FOLH1 43/4885CYP1A2 4418/4885 |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | NAALAD2 2657/4885FOLH1 475/4885CYP1A2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.